^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    2d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1021, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    3d
    Study on the resistance mechanism of ANGPTL4 mediated by NF-Kb/HIF-1 α to osimertinib in non-small cell lung cancer (ChiCTR2600117670)
    P=N/A, N=8, Not yet recruiting, Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital); Guangdong Second Provincial General Hospital (Guangdong Provin
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    A Prospective Study of the Bone Marrow Protective Effects of High-Dose Omega-3 Fatty Acids in the standard treatment regimen for Non-Small Cell Lung Cancer (ChiCTR2500111727)
    P=N/A, N=165, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    3d
    The efficacy and safety of tislelizumab combined with paclitaxel polymer micelles (pm-Pac) and carboplatin as first-line treatment for patients with locally advanced or advanced squamous non-small cell lung cancer. (ChiCTR2500113012)
    P4, N=47, Recruiting, Mianyang Central Hospital, Affiliated Hospital of University of Electronic Science and Technology of China; Mianyang Central Hospital, Affiliated Hosp
    New P4 trial
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr)
    3d
    A Prospective, Multicenter, Phase II Clinical Study of Lucansartuzumab Combined with Tislelizumab as Neoadjuvant Therapy for Resectable Stage II–IIIB NSCLC (ChiCTR2600116747)
    P2, N=45, Not yet recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation
    |
    Tevimbra (tislelizumab-jsgr) • Zepzelca (lurbinectedin)
    3d
    Lukangshatuzumab Adizutecan plus Tagolitinib as Neoadjuvant Therapy for Resectable Stage II–IIIB Squamous NSCLC: A Single-Center, Phase II Clinical Trial (neoTropIm) (ChiCTR2500112973)
    P2, N=33, Not yet recruiting, The Second Affiliated Hospital, Zhejiang University School of Medicine; The Second Affiliated Hospital, Zhejiang University School of Medicine
    New P2 trial
    3d
    A non-inferiority, randomized, controlled, multicenter, phase II clinical study was conducted to evaluate the efficacy and safety of triaciclib in the first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel or albumin-paclitaxel combined with carboplatin and tislelizumab (ChiCTR2500115243)
    P2, N=196, Not yet recruiting, Dongguan People's Hospital; Dongguan People's Hospital
    New P2 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Cosela (trilaciclib)
    3d
    A Phase II Clinical Study of JS207 (anti-PD-1/VEGF bispecific antibody) Combined with Platinum-based Doublet Chemotherapy in Subjects with Stage II-III Non-small Cell Lung Cancer (ChiCTR2500113936)
    P2, N=76, Recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • RET fusion • ALK fusion • ROS1 fusion
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed
    4d
    A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)
    P3, N=67, Active, not recruiting, Merck Sharp & Dohme LLC | N=160 --> 67 | Trial primary completion date: Jun 2026 --> Mar 2026
    Enrollment change • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    5d
    CA209-6K6: An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Montefiore Medical Center | Recruiting --> Active, not recruiting | N=52 --> 17 | Trial completion date: Jul 2025 --> May 2030
    Enrollment closed • Enrollment change • Trial completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed
    6d
    Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology. (PubMed, Cancers (Basel))
    The landscape of first-line treatment for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations is rapidly evolving, currently dominated by pembrolizumab-based regimens. Secondly, cemiplimab displays consistent, robust efficacy in challenging-to-treat squamous histology, both as monotherapy for patients with high PD-L1 expression and in combination with chemotherapy for patients with PD-L1 < 50%. In conclusion, cemiplimab establishes a unique therapeutic niche for patients with squamous histology and ultra-high PD-L1 expression, likely driven by its distinct structural stability and reduced immunogenicity.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc)
    7d
    TeLuRide-008: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (clinicaltrials.gov)
    P2/3, N=750, Not yet recruiting, Eikon Therapeutics
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • resiquimod sulfate (EIK1001)